The recent shift in terminology from NAFLD to metabolic dysfunction-associated steatotic liver disease (MASLD) has sharpened the focus on the metabolic factors underlying the condition, further emphasizing the importance of adipokines, such as chemerin [50,51]. This evidence concerns the gene RARRES2 and metabolic dysfunction-associated steatotic liver disease.